{
  "drug_name": "Anticoagulant_reversal_for_life-threatening_bleeds",
  "url": "https://wikem.org/wiki/Anticoagulant_reversal_for_life-threatening_bleeds",
  "scraped_at": "2026-01-10T07:47:51.246058",
  "sections": {
    "Factor_Xa_Inhibitor_Reversal": {
      "text": "^Off-label",
      "subsections": {
        "Andexanet_alfa": {
          "text": "FDA approved in May 2018, limited availability June 2018\nCost is $20,000 to $55,000 per dose\nTrial that led to FDA approval does not have the most sound evidence behind it\n[4]\n:\nProspective single center single group study of 352 patients receiving a Factor Xa Inhibitor (\napixaban\n,\nrivaroxaban\n,\nedoxaban\n,\nenoxaparin\n) with life threatening bleed (those with expected survival <1 month were excluded).\nAnti-Factor Xa activity was decreased in all groups. 82% were judged to have excellent hemostatic control. 14% mortality rate at 30 days.\nNo comparison group available. It is unlikely that following anti-Factor Xa activity as a lab value is clinically important. High mortality rate even after excluding sick patients.",
          "tables": []
        },
        "Low_Dose": {
          "text": "400\nmg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by\n4\nmg/minute for up to 120 minutes",
          "tables": []
        },
        "High_Dose": {
          "text": "800\nmg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by\n8\nmg/minute for up to 120 minutes",
          "tables": []
        },
        "Direct_Thrombin_Inhibitor": {
          "text": "",
          "tables": [
            [
              {
                "Anticoagulants": "Argatroban",
                "Half-life": "40-50 min",
                "Removed by HD": "~ 20%",
                "Strategies to reverse or minimize anticoagulant effects": "Turn off infusion"
              },
              {
                "Anticoagulants": "Bivalirudin(Angiomax®)",
                "Half-life": "25 min (up to 1 hr in severe renal impairment)",
                "Removed by HD": "~ 25%",
                "Strategies to reverse or minimize anticoagulant effects": "As above"
              },
              {
                "Anticoagulants": "Dabigatran[5](Pradaxa®)",
                "Half-life": "14-17 hrs (up to 34 hrs in severe renal impairment)",
                "Removed by HD": "~ 65%",
                "Strategies to reverse or minimize anticoagulant effects": "If ingested within 2 hours, administeractivated charcoalIdarucizumab(Praxbind®) 5g IVFor end stage renal disease patient with pre-existing vascular access, consult nephrology to consider dialysis."
              }
            ]
          ]
        },
        "Heparins": {
          "text": "",
          "tables": [
            [
              {
                "Anticoagulants": "Dalteparin(Fragmin®)",
                "Half-life": "3-5 hrs (longer in renal impairment)",
                "Removed by HD": "~ 20%",
                "Strategies to reverse or minimize anticoagulant effects": "Use protamine for partial neutralization (~60%)ProtamineIV:< 8 hours since last dose:Protamine50mg8-12 hours since last dose:Protamine25mg>12 hours since last dose: Unlikely useful unless CrCl < 30 mL/min (or 25mg fixed dose)Dose of protamine for each 100 units dalteparin or 1mg of enoxaparin administeredObtain baseline anti-Xa activity levelMonitor anti-Xa activity level to confirm reversal"
              },
              {
                "Anticoagulants": "Enoxaparin(Lovenox®)",
                "Half-life": "3-5 hrs (longer in renal impairment)",
                "Removed by HD": "~ 20%",
                "Strategies to reverse or minimize anticoagulant effects": "As above"
              },
              {
                "Anticoagulants": "Unfractionated heparin",
                "Half-life": "30-90 min (dose dependent)",
                "Removed by HD": "Partial",
                "Strategies to reverse or minimize anticoagulant effects": "Turn off infusionProtamine50mg IV"
              }
            ]
          ]
        },
        "Warfarin_(Coumadin®)": {
          "text": "",
          "tables": [
            [
              {
                "INR": "Any",
                "Clinical scenario": "Serious or life-threatening bleed",
                "Management": "HoldwarfarinGivevitamin K10mg IV infusion over 30 minutesGiveFFP/plasma orConsider 4-factorPCC(Kcentra™)—preferred for life-threatening bleeds"
              },
              {
                "INR": "> 10",
                "Clinical scenario": "No bleeding",
                "Management": "Hold warfarin until INR in therapeutic rangeConsidervitamin K2.5mg oral or 1-2mg IV infusion over 30 minutes (IV administration of vitamin K has faster onset of action)"
              },
              {
                "INR": "",
                "Clinical scenario": "Rapid reversal required",
                "Management": "Hold warfarinConsidervitamin K2.5mg oral or 1-2mg IV infusion over 30 minutes (IV administration of vitamin K has faster onset of action)"
              },
              {
                "INR": "4.5-10",
                "Clinical scenario": "No bleeding",
                "Management": "Hold warfarin until INR in therapeutic rangeConsidervitamin K2.5mg oral"
              },
              {
                "INR": "",
                "Clinical scenario": "Rapid reversal required",
                "Management": "Hold warfarinConsidervitamin K2.5mg oral or 1mg IV infusion (IV administration of vitamin K has faster onset of action)"
              },
              {
                "INR": "< 4.5",
                "Clinical scenario": "No bleeding",
                "Management": "Hold warfarin until INR in therapeutic range"
              },
              {
                "INR": "",
                "Clinical scenario": "Rapid reversal required",
                "Management": "Hold warfarinConsidervitamin K2.5mg oral"
              }
            ]
          ]
        }
      },
      "tables": [
        [
          {
            "Anticoagulant": "Apixaban[1](Eliquis®)",
            "Half-life": "8-15 hrs (longer in renal impairment)",
            "Removed by HD": "No",
            "Strategies to reverse or minimize anticoagulant effects": "If ingested within 2 hours, administer activated charcoal4-factorPCC(Kcentra™)^25units/kg—max 2500 units for treatment of documented intracranial hemorrhage50 units/kg—max 5000 units for all other life-threatening bleeds"
          },
          {
            "Anticoagulant": "Edoxaban[2](Savaysa®)",
            "Half-life": "10-14 hrs (longer in renal impairment)",
            "Removed by HD": "~ 25%",
            "Strategies to reverse or minimize anticoagulant effects": "As above"
          },
          {
            "Anticoagulant": "Rivaroxaban[3](Xarelto®)",
            "Half-life": "9-13 hrs (longer in renal impairment)",
            "Removed by HD": "No",
            "Strategies to reverse or minimize anticoagulant effects": "As above"
          },
          {
            "Anticoagulant": "Fondaparinux(Arixtra®)",
            "Half-life": "17-21 hrs (significantly longer in renal impairment)",
            "Removed by HD": "No",
            "Strategies to reverse or minimize anticoagulant effects": "4-factorPCC(Kcentra™)^ 50 units/kg—max 5000 units"
          }
        ]
      ],
      "links": [
        {
          "text": "apixaban",
          "url": "https://wikem.org/wiki/Apixaban"
        },
        {
          "text": "rivaroxaban",
          "url": "https://wikem.org/wiki/Rivaroxaban"
        },
        {
          "text": "edoxaban",
          "url": "https://wikem.org/wiki/Edoxaban"
        },
        {
          "text": "enoxaparin",
          "url": "https://wikem.org/wiki/Enoxaparin"
        }
      ]
    },
    "Andexanet_alfa": {
      "text": "FDA approved in May 2018, limited availability June 2018\nCost is $20,000 to $55,000 per dose\nTrial that led to FDA approval does not have the most sound evidence behind it\n[4]\n:\nProspective single center single group study of 352 patients receiving a Factor Xa Inhibitor (\napixaban\n,\nrivaroxaban\n,\nedoxaban\n,\nenoxaparin\n) with life threatening bleed (those with expected survival <1 month were excluded).\nAnti-Factor Xa activity was decreased in all groups. 82% were judged to have excellent hemostatic control. 14% mortality rate at 30 days.\nNo comparison group available. It is unlikely that following anti-Factor Xa activity as a lab value is clinically important. High mortality rate even after excluding sick patients.",
      "subsections": {
        "Low_Dose": {
          "text": "400\nmg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by\n4\nmg/minute for up to 120 minutes",
          "tables": []
        },
        "High_Dose": {
          "text": "800\nmg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by\n8\nmg/minute for up to 120 minutes",
          "tables": []
        },
        "Direct_Thrombin_Inhibitor": {
          "text": "",
          "tables": [
            [
              {
                "Anticoagulants": "Argatroban",
                "Half-life": "40-50 min",
                "Removed by HD": "~ 20%",
                "Strategies to reverse or minimize anticoagulant effects": "Turn off infusion"
              },
              {
                "Anticoagulants": "Bivalirudin(Angiomax®)",
                "Half-life": "25 min (up to 1 hr in severe renal impairment)",
                "Removed by HD": "~ 25%",
                "Strategies to reverse or minimize anticoagulant effects": "As above"
              },
              {
                "Anticoagulants": "Dabigatran[5](Pradaxa®)",
                "Half-life": "14-17 hrs (up to 34 hrs in severe renal impairment)",
                "Removed by HD": "~ 65%",
                "Strategies to reverse or minimize anticoagulant effects": "If ingested within 2 hours, administeractivated charcoalIdarucizumab(Praxbind®) 5g IVFor end stage renal disease patient with pre-existing vascular access, consult nephrology to consider dialysis."
              }
            ]
          ]
        },
        "Heparins": {
          "text": "",
          "tables": [
            [
              {
                "Anticoagulants": "Dalteparin(Fragmin®)",
                "Half-life": "3-5 hrs (longer in renal impairment)",
                "Removed by HD": "~ 20%",
                "Strategies to reverse or minimize anticoagulant effects": "Use protamine for partial neutralization (~60%)ProtamineIV:< 8 hours since last dose:Protamine50mg8-12 hours since last dose:Protamine25mg>12 hours since last dose: Unlikely useful unless CrCl < 30 mL/min (or 25mg fixed dose)Dose of protamine for each 100 units dalteparin or 1mg of enoxaparin administeredObtain baseline anti-Xa activity levelMonitor anti-Xa activity level to confirm reversal"
              },
              {
                "Anticoagulants": "Enoxaparin(Lovenox®)",
                "Half-life": "3-5 hrs (longer in renal impairment)",
                "Removed by HD": "~ 20%",
                "Strategies to reverse or minimize anticoagulant effects": "As above"
              },
              {
                "Anticoagulants": "Unfractionated heparin",
                "Half-life": "30-90 min (dose dependent)",
                "Removed by HD": "Partial",
                "Strategies to reverse or minimize anticoagulant effects": "Turn off infusionProtamine50mg IV"
              }
            ]
          ]
        },
        "Warfarin_(Coumadin®)": {
          "text": "",
          "tables": [
            [
              {
                "INR": "Any",
                "Clinical scenario": "Serious or life-threatening bleed",
                "Management": "HoldwarfarinGivevitamin K10mg IV infusion over 30 minutesGiveFFP/plasma orConsider 4-factorPCC(Kcentra™)—preferred for life-threatening bleeds"
              },
              {
                "INR": "> 10",
                "Clinical scenario": "No bleeding",
                "Management": "Hold warfarin until INR in therapeutic rangeConsidervitamin K2.5mg oral or 1-2mg IV infusion over 30 minutes (IV administration of vitamin K has faster onset of action)"
              },
              {
                "INR": "",
                "Clinical scenario": "Rapid reversal required",
                "Management": "Hold warfarinConsidervitamin K2.5mg oral or 1-2mg IV infusion over 30 minutes (IV administration of vitamin K has faster onset of action)"
              },
              {
                "INR": "4.5-10",
                "Clinical scenario": "No bleeding",
                "Management": "Hold warfarin until INR in therapeutic rangeConsidervitamin K2.5mg oral"
              },
              {
                "INR": "",
                "Clinical scenario": "Rapid reversal required",
                "Management": "Hold warfarinConsidervitamin K2.5mg oral or 1mg IV infusion (IV administration of vitamin K has faster onset of action)"
              },
              {
                "INR": "< 4.5",
                "Clinical scenario": "No bleeding",
                "Management": "Hold warfarin until INR in therapeutic range"
              },
              {
                "INR": "",
                "Clinical scenario": "Rapid reversal required",
                "Management": "Hold warfarinConsidervitamin K2.5mg oral"
              }
            ]
          ]
        }
      },
      "tables": [],
      "links": [
        {
          "text": "apixaban",
          "url": "https://wikem.org/wiki/Apixaban"
        },
        {
          "text": "rivaroxaban",
          "url": "https://wikem.org/wiki/Rivaroxaban"
        },
        {
          "text": "edoxaban",
          "url": "https://wikem.org/wiki/Edoxaban"
        },
        {
          "text": "enoxaparin",
          "url": "https://wikem.org/wiki/Enoxaparin"
        }
      ]
    },
    "Direct_Thrombin_Inhibitor": {
      "text": "",
      "subsections": {
        "Heparins": {
          "text": "",
          "tables": [
            [
              {
                "Anticoagulants": "Dalteparin(Fragmin®)",
                "Half-life": "3-5 hrs (longer in renal impairment)",
                "Removed by HD": "~ 20%",
                "Strategies to reverse or minimize anticoagulant effects": "Use protamine for partial neutralization (~60%)ProtamineIV:< 8 hours since last dose:Protamine50mg8-12 hours since last dose:Protamine25mg>12 hours since last dose: Unlikely useful unless CrCl < 30 mL/min (or 25mg fixed dose)Dose of protamine for each 100 units dalteparin or 1mg of enoxaparin administeredObtain baseline anti-Xa activity levelMonitor anti-Xa activity level to confirm reversal"
              },
              {
                "Anticoagulants": "Enoxaparin(Lovenox®)",
                "Half-life": "3-5 hrs (longer in renal impairment)",
                "Removed by HD": "~ 20%",
                "Strategies to reverse or minimize anticoagulant effects": "As above"
              },
              {
                "Anticoagulants": "Unfractionated heparin",
                "Half-life": "30-90 min (dose dependent)",
                "Removed by HD": "Partial",
                "Strategies to reverse or minimize anticoagulant effects": "Turn off infusionProtamine50mg IV"
              }
            ]
          ]
        },
        "Warfarin_(Coumadin®)": {
          "text": "",
          "tables": [
            [
              {
                "INR": "Any",
                "Clinical scenario": "Serious or life-threatening bleed",
                "Management": "HoldwarfarinGivevitamin K10mg IV infusion over 30 minutesGiveFFP/plasma orConsider 4-factorPCC(Kcentra™)—preferred for life-threatening bleeds"
              },
              {
                "INR": "> 10",
                "Clinical scenario": "No bleeding",
                "Management": "Hold warfarin until INR in therapeutic rangeConsidervitamin K2.5mg oral or 1-2mg IV infusion over 30 minutes (IV administration of vitamin K has faster onset of action)"
              },
              {
                "INR": "",
                "Clinical scenario": "Rapid reversal required",
                "Management": "Hold warfarinConsidervitamin K2.5mg oral or 1-2mg IV infusion over 30 minutes (IV administration of vitamin K has faster onset of action)"
              },
              {
                "INR": "4.5-10",
                "Clinical scenario": "No bleeding",
                "Management": "Hold warfarin until INR in therapeutic rangeConsidervitamin K2.5mg oral"
              },
              {
                "INR": "",
                "Clinical scenario": "Rapid reversal required",
                "Management": "Hold warfarinConsidervitamin K2.5mg oral or 1mg IV infusion (IV administration of vitamin K has faster onset of action)"
              },
              {
                "INR": "< 4.5",
                "Clinical scenario": "No bleeding",
                "Management": "Hold warfarin until INR in therapeutic range"
              },
              {
                "INR": "",
                "Clinical scenario": "Rapid reversal required",
                "Management": "Hold warfarinConsidervitamin K2.5mg oral"
              }
            ]
          ]
        }
      },
      "tables": [
        [
          {
            "Anticoagulants": "Argatroban",
            "Half-life": "40-50 min",
            "Removed by HD": "~ 20%",
            "Strategies to reverse or minimize anticoagulant effects": "Turn off infusion"
          },
          {
            "Anticoagulants": "Bivalirudin(Angiomax®)",
            "Half-life": "25 min (up to 1 hr in severe renal impairment)",
            "Removed by HD": "~ 25%",
            "Strategies to reverse or minimize anticoagulant effects": "As above"
          },
          {
            "Anticoagulants": "Dabigatran[5](Pradaxa®)",
            "Half-life": "14-17 hrs (up to 34 hrs in severe renal impairment)",
            "Removed by HD": "~ 65%",
            "Strategies to reverse or minimize anticoagulant effects": "If ingested within 2 hours, administeractivated charcoalIdarucizumab(Praxbind®) 5g IVFor end stage renal disease patient with pre-existing vascular access, consult nephrology to consider dialysis."
          }
        ]
      ],
      "links": []
    },
    "Heparins": {
      "text": "",
      "subsections": {
        "Warfarin_(Coumadin®)": {
          "text": "",
          "tables": [
            [
              {
                "INR": "Any",
                "Clinical scenario": "Serious or life-threatening bleed",
                "Management": "HoldwarfarinGivevitamin K10mg IV infusion over 30 minutesGiveFFP/plasma orConsider 4-factorPCC(Kcentra™)—preferred for life-threatening bleeds"
              },
              {
                "INR": "> 10",
                "Clinical scenario": "No bleeding",
                "Management": "Hold warfarin until INR in therapeutic rangeConsidervitamin K2.5mg oral or 1-2mg IV infusion over 30 minutes (IV administration of vitamin K has faster onset of action)"
              },
              {
                "INR": "",
                "Clinical scenario": "Rapid reversal required",
                "Management": "Hold warfarinConsidervitamin K2.5mg oral or 1-2mg IV infusion over 30 minutes (IV administration of vitamin K has faster onset of action)"
              },
              {
                "INR": "4.5-10",
                "Clinical scenario": "No bleeding",
                "Management": "Hold warfarin until INR in therapeutic rangeConsidervitamin K2.5mg oral"
              },
              {
                "INR": "",
                "Clinical scenario": "Rapid reversal required",
                "Management": "Hold warfarinConsidervitamin K2.5mg oral or 1mg IV infusion (IV administration of vitamin K has faster onset of action)"
              },
              {
                "INR": "< 4.5",
                "Clinical scenario": "No bleeding",
                "Management": "Hold warfarin until INR in therapeutic range"
              },
              {
                "INR": "",
                "Clinical scenario": "Rapid reversal required",
                "Management": "Hold warfarinConsidervitamin K2.5mg oral"
              }
            ]
          ]
        }
      },
      "tables": [
        [
          {
            "Anticoagulants": "Dalteparin(Fragmin®)",
            "Half-life": "3-5 hrs (longer in renal impairment)",
            "Removed by HD": "~ 20%",
            "Strategies to reverse or minimize anticoagulant effects": "Use protamine for partial neutralization (~60%)ProtamineIV:< 8 hours since last dose:Protamine50mg8-12 hours since last dose:Protamine25mg>12 hours since last dose: Unlikely useful unless CrCl < 30 mL/min (or 25mg fixed dose)Dose of protamine for each 100 units dalteparin or 1mg of enoxaparin administeredObtain baseline anti-Xa activity levelMonitor anti-Xa activity level to confirm reversal"
          },
          {
            "Anticoagulants": "Enoxaparin(Lovenox®)",
            "Half-life": "3-5 hrs (longer in renal impairment)",
            "Removed by HD": "~ 20%",
            "Strategies to reverse or minimize anticoagulant effects": "As above"
          },
          {
            "Anticoagulants": "Unfractionated heparin",
            "Half-life": "30-90 min (dose dependent)",
            "Removed by HD": "Partial",
            "Strategies to reverse or minimize anticoagulant effects": "Turn off infusionProtamine50mg IV"
          }
        ]
      ],
      "links": []
    },
    "See_Also": {
      "text": "Coagulopathy (main)\nAnti-platelet agent reversal",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Coagulopathy (main)",
          "url": "https://wikem.org/wiki/Coagulopathy_(main)"
        },
        {
          "text": "Anti-platelet agent reversal",
          "url": "https://wikem.org/wiki/Anti-platelet_agent_reversal"
        }
      ]
    },
    "External_Links": {
      "text": "JournalFeed Summary with Flowsheet\nof ”Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel.” by Baugh et. al. from Annals 2019\n[6]",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "References": {
      "text": "Harbor-UCLA Medical Center Guidelines Approved by Anticoagulation Subcommittee on 3/17/2016 Approved by Pharmacy and Therapeutic Committee on 3/17/2016\nHatfield L and Chen SL. University of North Carolina Healthcare Anticoagulation Reversal Guidelines. June 2014.",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}